Related Experiment Video

Updated: May 2, 2026

Protein Misfolding Cyclic Amplification of Prions
10:12

Protein Misfolding Cyclic Amplification of Prions

Published on: November 7, 2012

18.8K

Anti-amyloid compounds inhibit α-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA)

Maria Eugenia Herva1, Shahin Zibaee2, Graham Fraser2

  • 1John Van Geest Centre for Brain Repair, E. D. Adrian Building, Robinson Way, Cambridge CB2 0PY, United Kingdom.

The Journal of Biological Chemistry
|March 4, 2014
PubMed

Insights

Protein misfolding cyclic amplification (PMCA) can rapidly grow alpha-synuclein aggregates for Parkinson's disease research. This new method enables high-throughput screening for drugs to combat alpha-synuclein aggregation and treat neurodegenerative diseases.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Drug Discovery

Background:

  • Alpha-synuclein filaments form Lewy pathology in Parkinson's disease and related disorders.
  • Current in vitro methods for alpha-synuclein filament formation are slow and variable, hindering drug screening.
  • Developing rapid and reproducible methods for studying alpha-synuclein aggregation is crucial for therapeutic development.

Purpose of the Study:

  • To adapt the protein misfolding cyclic amplification (PMCA) technique for efficient alpha-synuclein aggregate formation.
  • To establish a high-throughput screening assay for drugs targeting alpha-synuclein aggregation.
  • To investigate the potential of PMCA-generated alpha-synuclein aggregates for disease modeling and drug discovery.

Main Methods:

  • Utilized protein misfolding cyclic amplification (PMCA) to generate alpha-synuclein aggregates.
  • Employed circular dichroism, electron microscopy, and gel electrophoresis to characterize aggregates.
  • Assessed the seeding capacity and cellular uptake of PMCA-generated alpha-synuclein fibrils.
  • Tested a panel of drugs for their ability to inhibit PMCA-induced alpha-synuclein aggregation.

Main Results:

  • Demonstrated successful alpha-synuclein aggregate formation using the PMCA technique.
  • Confirmed that PMCA-generated fibrils can seed new reactions and aggregate within cultured cells.
  • Generated a cell line with persistent alpha-synuclein aggregates, indicating stable propagation.
  • Identified anti-amyloid compounds as effective inhibitors of PMCA-induced alpha-synuclein fibril formation.

Conclusions:

  • Alpha-synuclein PMCA is a rapid and reproducible method for generating disease-relevant aggregates.
  • This PMCA system is suitable for high-throughput screening of anti-aggregation compounds.
  • The developed method offers a promising avenue for discovering new therapeutics for alpha-synucleinopathies.
Keywords:
AmyloidCell TherapyDrug ScreeningPMCAProtein Aggregationα-Synuclein

More Related Videos

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.2K
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

11.1K

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
10.2K
Amyloid Fibrils03:03

Amyloid Fibrils

5.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K